blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP2530089

EP2530089 - Neutralising prolactin receptor antibody Mat3 and its therapeutical use [Right-click to bookmark this link]
StatusThe application has been withdrawn
Status updated on  01.02.2013
Database last updated on 11.09.2024
Most recent event   Tooltip01.02.2013Withdrawal of applicationpublished on 06.03.2013  [2013/10]
Applicant(s)For all designated states
Bayer Pharma Aktiengesellschaft
Müllerstrasse 178
13353 Berlin / DE
[2012/49]
Inventor(s)01 / Freiberg, Christoph
Bayer Schering Pharma Aktiengesellschaft
BSP-GDD-GB-BRG-PBC
Protein Expression&Cell Line Developm. 2
Lipkenskothen 10
42113 Wuppertal / DE
02 / Otto, Christiane
Bayer Schering Pharma AG
GDD-GTR-WHC-FFC Femals
Fertility Control & MM 5
Monbijouplatz 9
10178 Berlin / DE
03 / Linden, Lars
Bruchstrasse 72
40235 Düsseldorf / DE
04 / Harrenga, Alex
Bayer Schering Pharma AG
BSP-GDD-GB-BRG-PBC
Protein Expression&Cell Line Developm. 2
Sadowastrasse 17
42115 Wuppertal / DE
05 / Trautwein, Mark
Bayer Schering Pharma AG
BSP-GDD-GB-BRG-PBC
Protein Expression&Cell Line Developm. 2
Nelkenweg 2
42489 Wülfrath / DE
06 / Greven, Simone
Bayer Schering Pharma AG
BSP-GDD-GB-BRG-PBC
Protein Expression&Cell Line Developm. 2
Am Schneckenacker 45
41541 Dormagen / DE
07 / Wilmen, Andreas
Bayer Schering Pharma AG
BSP-GDD-GB-BRG-PBC
Protein Expression&Cell Line Developm. 2
Arndtstrasse 5
50676 Köln / DE
 [2012/49]
Application number, filing date11168644.003.06.2011
[2012/49]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2530089
Date:05.12.2012
Language:EN
[2012/49]
Search report(s)(Supplementary) European search report - dispatched on:EP03.11.2011
ClassificationIPC:C07K16/28, A61K39/395, A61P5/00
[2012/49]
CPC:
C07K16/2869 (EP,US); C07K16/28 (KR); A61K39/395 (KR);
A61K39/3955 (US); A61K45/06 (US); A61P13/08 (EP);
A61P15/00 (EP); A61P15/18 (EP); A61P17/14 (EP);
A61P35/00 (EP); A61P5/00 (EP); A61P5/08 (EP);
C07K16/3015 (US); A61K2039/505 (EP,US); C07K2317/21 (EP,US);
C07K2317/33 (EP,US); C07K2317/34 (EP,US); C07K2317/565 (US);
C07K2317/73 (EP,US); C07K2317/76 (US); C07K2317/92 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2012/49]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:Neutralisierender Antikörper Mat3 gegen den Prolactinrezeptor und dessen therapeutische Verwendung[2012/49]
English:Neutralising prolactin receptor antibody Mat3 and its therapeutical use[2012/49]
French:Anticorps neutralisant Mat3 contre le récepteur de prolactine et son utilisation thérapeutique[2012/49]
Examination procedure16.08.2011Despatch of communication that the application is deemed to be withdrawn, reason: filing fee / search fee not paid in time
31.01.2013Application withdrawn by applicant  [2013/10]
Request for further processing for:The application is deemed to be withdrawn due to non-payment of the search fee
01.09.2011Request for further processing filed
01.09.2011Full payment received (date of receipt of payment)
Request granted
21.10.2011Decision despatched
The application is deemed to be withdrawn due to non-payment of the filing fee
01.09.2011Request for further processing filed
01.09.2011Full payment received (date of receipt of payment)
Request granted
21.10.2011Decision despatched
01.09.2011Request for further processing filed
01.09.2011Full payment received (date of receipt of payment)
Request granted
21.10.2011Decision despatched
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[ID]US2007269438  (ELENBAAS BRIAN [US], et al) [ID] 1-27 * example - *;
 [ID]WO2008022295  (NOVARTIS AG [CH], et al) [ID] 1-27 * example - *;
 [T]EP2332995  (BAYER SCHERING PHARMA AG [DE]) [T] * the whole document *;
 [ID]  - J. SISSOM ET AL., "Anti-growth action on mouse mammary and prostate glands of a monoclonal antibody to prolactin receptor.", AMERICAN JOURNAL OF PATHOLOGY, U.S.A., (198812), vol. 133, no. 3, pages 589 - 595, XP008068076 [ID] 1-27 * abstract *
 [A]  - J. SISSOM-DEMORE ET AL., "A monoclonal antibody to prolactin receptor inhibits proliferation of breast cancer cells.", THE FASEB JOURNAL, U.S.A., (19960606), vol. 10, no. 6, page A1389, XP008113243 [A] 1-27 * abstract 2244 *
by applicantUS4399216
 US4510245
 US4634665
 US4657760
 US4816567
 US4968615
 US5168062
 US5179017
 US5206344
 US5225212
 US5766886
 US6300064
 WO03004989
 WO03008583
 US6989250
 WO2006110585
 US2007269438
 WO2008022295
    - BIOESSAYS, (2006), vol. 28, pages 1051 - 1055
    - ENDOCRINE REVIEWS, (1998), vol. 19, pages 225 - 268
    - ANNU. REV. PHYSIOL., (2002), vol. 64, pages 47 - 67
    - NATURE CLINICAL PRACTICE ENDOCRINOLOGY AND METABOLISM, (2006), vol. 2, no. 10, pages 571 - 581
    - BREAST CANCER RES. TREAT., (1989), vol. 14, pages 289 - 29
    - LUPUS, (1998), vol. 7, pages 414 - 419
    - AM J PATHOL, (1988), vol. 133, pages 589 - 595
    - PITUITARY, (2003), vol. 6, pages 89 - 95
    - ACTA OBSTET GYNECOL SCAND, (2002), vol. 81, pages 5 - 10
    - RETTER, ALTHAUS HH, MUNCH R, MOLLER W, "VBASE2, an integrative V gene database", NUCLEIC ACIDS RES., (20050101), vol. 33, pages D671 - 4
    - PNAS, (2008), vol. 105, no. 38, page 14533
    - J. CLIN. ENDOCRINOL. METAB., (2010), vol. 95, no. 1, page 271
    - S6DERLIND ET AL., NATURE BIOTECHNOLOGY, (2000), vol. 18, pages 852 - 856
    - ROETHLISBERGER, D. ET AL., J. MOL. BIOL., (2005), vol. 347, pages 773 - 789
    - VIRNEKAS, B., GE, L., P ÜCKTHUN, A., SCHNEIDER, K.C., WELLNHOFER, G., MORONEY S.E., "Trinucleotide phosphoramidites: ideal reagents for the synthesis of mixed oligonucleotides for random mutagenesis", NUCL. ACIDS RES., (1994), vol. 22, page 5600
    - KHORANA ET AL., J. MOL. BIOL., (1971), vol. 72, pages 209 - 217
    - URLAUB, CHASIN, PROC. NATL. ACAD. SCI. USA, (1980), vol. 77, pages 4216 - 4220
    - R. J. KAUFMAN, P. A. SHARP, MOL. BIOL., (1982), vol. 159, pages 601 - 621
    - COLLIGAN, Current Protocols in Immunology
    - OBSTET. GYNECOL. CLIN. NORTH. AM., (1997), vol. 24, pages 235 - 238
    - HUM. REPROD., (2002), vol. 17, no. 19, pages 2715 - 2724
    - OBSTET. GYNECOL., (1984), vol. 64, pages 151 - 154
    - FERTIL. STERIL., (1998), vol. 69, pages 1042 - 1047
    - BRITISH JOURNAL OF PHARMACOLOGY, (2006), vol. 149, pages 133 - 135
    - LIFE SCIENCES, (1992), vol. 51, pages 1119 - 1125
    - EPIDEMIOL REV, (1997), vol. 19, pages 310 - 327
    - J MAMMARY, GLAND BIOL NEOPLASIA, (2005), vol. 10, pages 325 - 335
    - ZENTRALBL GYNAKOL, (1997), vol. 119, pages 54 - 58
    - AM J OBSTET GYNECOL, (1986), vol. 154, pages 161 - 179
    - AM J OBSTET, (1986), vol. 154, pages 161 - 179
    - CLIN ENDOCRINOL, (1985), vol. 23, pages 699 - 704
    - PROC NATL ACAD SCI, (2008), vol. 105, pages 14533 - 14538
    - METHODS IN MAMMARY GLAND BIOLOGY AND BREAST CANCER RESEARCH, (2000), pages 101 - 107
    - GENES DEV, (1997), vol. 11, pages 167 - 178
    - HUMAN REPROD., (2004), vol. 19, pages 1911 - 1916
    - HUMAN REPROD., (2003), vol. 18, pages 2672 - 2677
    - FRONTIERS, NEUROENDOCRINOLOGY, (2001), vol. 22, pages 140 - 145
    - ENDOCRINOLOGY, (1978), vol. 102, pages 1657 - 1661
    - J. CLIN. INVEST., (1997), vol. 99, page 618
    - ENDOCRINOLOGY, (1997), vol. 138, page 4410
    - ENDOCRINOLOGY, (2003), vol. 144, page 2269
    - JAMA, (2002), vol. 233, pages 321 - 333
    - CLEVELAND CLINIC JOURNAL OF MEDICINE, (2009), vol. 76, pages 361 - 367
    - BRITISH JOURNAL OF DERMATOLOGY, (2008), vol. 159, pages 300 - 305
    - AKTUELLE DERMATOLOGIE, (2005), vol. 31, pages 109 - 116
    - J CLIN ENDOCRINOL METAB, (1998), vol. 83, pages 667 - 674
    - INT. J. CANCER, (1993), vol. 55, no. 5, pages 712 - 721
    - CANCER LETT, (2006), vol. 243, pages 160 - 169
    - EUR J SURG ONCOL, (1994), vol. 20, pages 118 - 121
    - J CLIN INVEST, (1997), vol. 100, pages 2744 - 2751
    - PAUL KELLY, PROC NATL ACAD SCI U S A., (2008), vol. 105, no. 38, pages 14533 - 14538
    - SCATCHARD ET AL., ANN N.Y. ACAD. SCL, (1949), vol. 51, page 660
    - LABRIJN ET AL., CURRENT OPINION IN IMMUNOLOGY, (2008), vol. 20, pages 479 - 485
    - SAZINSKY ET AL., PROC. NAT. ACAD. SCI., (2008), vol. 105, no. 51, page 20169
    - SIMMONS ET AL., J. OF IMMUNOLOGICAL METHODS, (2002), vol. 263, pages 133 - 147
    - HEZAREH ET AL., J. OF VIROLOGY, (2001), vol. 75, no. 24, pages 12161 - 12168
    - SCHUURMAN, J. ET AL., IMMUNOLOGY, (1999), vol. 97, pages 693 - 698
    - ALLEN ET AL., BIOCHEMISTRY, (2009), vol. 48, no. 17, pages 3755 - 3766
    - AN ET AL., MABS, (2009), vol. 1, no. 6
    - KOHLER ET AL., NATURE, (1975), vol. 256, page 495
    - JOHNSON, WU, NUCLEIC ACIDS RES., (2000), vol. 28, pages 214 - 218
    - CHOTHIA ET AL., J. MOL.BIOL., (1987), vol. 196, pages 901 - 917
    - ZAPATA ET AL., PROTEIN ENG., (1995), vol. 8, no. 10, pages 1057 - 1062
    - PLUCKTHUN, The Pharmacology of Monoclonal Antibodies, SPRINGER-VERLAG, (1994), vol. 113, pages 269 - 315
    - CARLSSON, S6DERLIND, EXP. REV. MOL. DIAGN., (2001), vol. 1, no. 1, pages 102 - 108
    - S6DERLIN ET AL., NAT. BIOTECH., (2000), vol. 18, pages 852 - 856
    - KNAPPIK ET AL., J. MOL. BIOL., (2000), vol. 296, page 57
    - KREBS ET AL., J. IMMUNOL. METHODS, (2001), vol. 254, page 67
    - REMINGTON'S PHARMACEUTICAL SCIENCES, MACK PUB. CO., (1990), pages 484 - 528
    - Remington's Pharmaceutical Sciences, MAACK PUBLISHING CO
    - RIVA ET AL., CLIN. CANCER RES., (1999), vol. 5, pages 3275S - 3280S
    - WONG ET AL., CLIN. CANCER RES., (2000), vol. 6, pages 3855 - 3863
    - WAGNER ET AL., J. NUCLEAR MED., (2002), vol. 43, pages 267 - 272
    - ENDOCRINOLGY, (2008), vol. 149, no. 8, pages 3952 - 3959
    - LABORATORY ANIMAL SCIENCE, (1998), vol. 48, pages 64 - 68
    - ENDOCRINOLOGY, (2009), vol. 149, no. 8, pages 3952 - 3959
    - MARKS ET AL., METHODS MOL BIOL., (2004), vol. 248, pages 161 - 76
    - METHODS MOL BIOL., (2004), vol. 248, pages 161 - 76
    - BMC BIOTECHNOLOGY, (2007), vol. 7, page 65
    - TIMMERMAN ET AL., J. MOL. RECOGNIT., (2007), vol. 20, pages 283 - 99
    - SLOOTSTRA ET AL., MOLECULAR DIVERSITY, (1996), vol. 1, pages 87 - 96
    - "Expressing complex relationships in two dimensions", GOWER, DIGBY, Interpreting Multivariate Data, JOHN WILEY & SONS, (1981), pages 83 - 118
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.